This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Pancreatic cancer	Nuclear receptor subfamily 5 group A member 2 (NR5A2; LRH-1)	*In vitro* studies suggest inhibiting LRH-1 could help treat pancreatic cancer. In tumor tissue from pancreatic cancer patients, LRH-1 levels were greater than those in pancreatic tissue from healthy controls. In metastatic pancreatic cancer cell lines expressing LRH-1, small interfering RNA against *LRH-1* inhibited cell proliferation compared with scrambled siRNA controls. Future studies could include testing LRH-1 inhibition in animal models of pancreatic cancer. *SciBX* 4(39); doi:10.1038/scibx.2011.1088 Published online Oct. 6, 2011	Patent and licensing status unavailable	Benod, C. *et al. Proc. Natl. Acad. Sci. USA*; published online Sept. 26, 2011; doi:10.1073/pnas.1112047108 **Contact:** Robert J. Fletterick, University of California, San Francisco, Calif. e-mail: Robert.Fletterick@ucsf.edu